Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13050MR)

This product GTTS-WQ13050MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13050MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3264MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ6906MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ10514MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ7190MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ12831MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ9046MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ934MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ15595MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW